ALMS

If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.

New Phase 3 Data Demonstrates Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population.

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc.

Alumis stock presents a sharp disconnect between recent share price swings and what broad valuation checks suggest.

In early September 2026, Alumis reported that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet primary and secondary endpoints in the overall patient population, despite a favorable safety profile over 48 weeks.

Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses.

Alumis (NasdaqGS: ALMS) reported that its lead drug envudeucitinib did not meet primary or secondary endpoints in a Phase 2b lupus trial.

Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitini

The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.